The UAB Gregory Fleming James Cystic Fibrosis Research Center is a university-wide interdisciplinary research center funded by the National Institutes of Health, the Cystic Fibrosis Foundation, and ...
Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...
In December, the FDA approved Vertex’s vanzacaftor, tezacaftor and deutivacaftor (Alyftrek) for the treatment of cystic fibrosis in patients with at least one F508del mutation or another ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback